ClinicalTrials.gg
RecruitingNCT06395441Updated Oct 20, 2026

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

A Phase 3 interventional study of American Ginseng and Placebo Administration in Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia and Hematopoietic and Lymphatic System Neoplasm, sponsored by Mayo Clinic. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Mayo Clinic · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 20, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic — 8 open to participants now, 12 under way, 1 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Mayo Clinic.

Planned enrollment
5th of 36
222 · median 40
Started
2024
with 2 others
Phase 3
2 of 45
1 open now
Primary completion
2027-12
later than 4 of 11 live
Registered
43rd of 45
by date

Among the 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic, this one is the 5th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 43rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Mayo Clinic, or all of them as a file.
02

Study summary

This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fatigue is among the most challenging symptoms to manage in patients with cancer, both on or off active treatment. This symptom complex meaningfully contributes to psychosocial distress, healthcare costs, and it also interferes with the delivery of anticancer therapies. American ginseng (Western ginseng) appears to be a promising appearing agent for treating cancer related fatigue. Western ginseng may reduce cancer-related fatigue.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the efficacy of ginseng as assessed by a single item measure of fatigue at 8 weeks.

SECONDARY OBJECTIVES:

I. To estimate changes in fatigue via the single item measure of fatigue from baseline to week 4, the Global Impression of Change at week 4 and 8, and the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) at week 4 and 8.

II. To evaluate the frequency and severity of toxicity as reported by the patient on the Ginseng Symptom Experience Diary where patients rate (on a 0 to 10 scale) their toxicities experienced while on study.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive Western ginseng orally (PO) twice daily (BID) on days 1-56.

GROUP II: Patients receive placebo PO BID on days 1-56.

03

Conditions studied

  • Malignant Solid Neoplasm
  • Chronic Lymphocytic Leukemia
  • Hematopoietic and Lymphatic System Neoplasm
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • GROUP 1 PARTICIPANTS: Has received or is receiving treatment for a solid-organ (does not apply to Group 2)
  • GROUP 2 PARTICIPANTS: Diagnosis of one of the following hematologic malignancies: Chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), multiple myeloma, or survivorship care after completion of therapy for one of the above hematologic malignancies (within 5 years of completion of therapy)
  • History of cancer-related fatigue as defined by an average score ≥ 4 over the past 30 days on the numeric analogue scale. Patients can answer questions orally rather than completing worksheet
  • Baseline control of insomnia: Insomnia ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
  • Baseline control of pain: Pain ≤ 4 on Linear Analogue Scale. Patients can answer questions orally rather than completing worksheet
  • ≥ 6 months
  • (ECOG) performance status (PS) 0, 1 or 2
  • GROUP 1 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to hematologic malignancies)

    • ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
    • (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal ()
    • Creatinine ≤ 1.5 x ULN
  • GROUP 2 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to solid-organ malignancies):

    • Hemoglobin ≥ 8.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
    • count ≥ 50,000 cells/mm\^3
    • ≥ 1000 cells/mm\^3
    • Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x ULN
    • Creatinine ≤ 1.5 x ULN
  • No clinical suspicion of hypothyroidism within 180 days prior to registration (if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone [TSH] \< 5 mIU/L is required)
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons of only
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Any known to ginseng
  • Currently using any other pharmacologic agents to specifically treat fatigue including psychostimulants or antidepressants. Note: Antidepressants used to treat items other than fatigue (such as hot flashes or depression) are allowed if the patient has been on a stable dose for ≥ 30 days and plan to continue such for 8 weeks. Exercise is allowed
  • Psychiatric disorder such as poorly controlled depression, manic depressive disorder, obsessive compulsive disorder, or schizophrenia (defined per medical history)
  • Use of erythropoietic agents ≤ 6 months
  • Uncontrolled hypertension on more than three occasions (diastolic blood pressure ≥ 100, systolic ≥ 160) measured ≤ 180 days prior to randomization
  • Surgery that required general anesthetic ≤ 30 days prior to randomization
  • Malnutrition, active infection, severe depression, or significant pulmonary disease and cardiovascular disease (as determined by the attending clinician), as they could impact fatigue
  • Use of any over the counter herbal/dietary supplement marketed for fatigue or energy (for example, products containing any type of ginseng, Rhodiola rosea, guarana, or anything called an "adaptogen")
  • Currently using an antidiabetic drug, warfarin or monamine oxide inhibitor

    • Examples of antidiabetic drugs include: Insulin, sulfonylureas, sodium-glucose co-transporter subtype 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonists/dual incretin agonists, and related agents
  • Treating provider anticipates a change to the anti-cancer treatment program in the next 8 weeks (i.e., the intervention period)
  • Any of the following because this study involves an agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of who are unwilling to employ adequate . (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
  • GROUP 2 PARTICIPANTS: Patients who have been hospitalized (> 24 hours) in the previous 2 months or who will require hospitalization (for anti-cancer therapy) within the next 3 months
  • GROUP 2 PARTICIPANTS: Prior transplant
  • GROUP 2 PARTICIPANTS: Chimeric antigen receptor T cell (CAR-T), or autologous transplant within the last 180 days
  • GROUP 2 PARTICIPANTS: T-cell engager initiation within the last 3 months (patients on stable maintenance dosing are permitted)
  • GROUP 2 PARTICIPANTS: Enrolled in another interventional clinical trial
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
222 participants (estimated)

Study arms

  • Experimental
    Group I (Western ginseng)

    Patients receive Western ginseng PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity.

    Dietary Supplement: American Ginseng · Other: Questionnaire Administration

  • Placebo comparator
    Group II (placebo)

    Patients receive placebo PO BID on days 1-56. Treatment continues in the absence of disease progression or unacceptable toxicity.

    Drug: Placebo Administration · Other: Questionnaire Administration

Interventions

  • Dietary supplementAmerican Ginseng

    Given PO

    Also known as: Ginseng, Ginseng Root, Panax quinquifolius

  • DrugPlacebo Administration

    Given PO

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Change in fatigue at 8 weeks

    Will be measured by the Linear Analog Scale for Fatigue, a single-item questionnaire rating fatigue over the pats week on a scale of 0-10 where 0=no fatigue at all and 10=fatigue as bad as it can be.

    Time frame: Baseline to 8 weeks

Secondary outcomes

  1. Percentage of patients who perceive moderate to very much better fatigue

    Will be measured by the Global Impression of Change scale, which consists of 3 questions answered on a scale of -3 (very much worse) to 3 (very much better), one question as to whether the participants thought they were receiving the intervention (ginseng) or placebo, and one question related to satisfaction with the effect of the treatment on their fatigue (yes/no).

    Time frame: 4 weeks, 8 weeks

  2. Change in Fatigue - FACIT-Fatigue

    Will be measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, which consists of 13 questions answered on a scale of 0-4 where 0=not at all and 4=very much.

    Time frame: 4 weeks, 8 weeks

  3. Patient-reported Toxicities - Ginseng Symptom Experience Diary

    Will be measured using the Ginseng Symptom Experience Diary, where patients rate toxicities experienced while on study. The diary asks patients to rate a list of 7 symptoms over the past week on a scale of 0 (none at all) to 10 (as bad as it can be), with higher scores indicating greater severity of symptoms.

    Time frame: Up to 8 weeks

07

Study locations

14 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

Of 83 phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 76. This study's planned 40 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Nov 2026 → Dec 2027 and completion Nov 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 2, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Dec 30, 2027was Nov 2026
CompletionEst.
Dec 30, 2027was Nov 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Dec 30, 2027
Oct 6, 2026
Study completion
Nov 30, 2026→Dec 30, 2027
Oct 6, 2026
Enrollment
160→222
Oct 20, 2026
Eligibility
5 inclusion criteria edited, 8 added; 10 exclusion criteria added
What changed in the criteria
Inclusion criteria
  • EditedGROUP 1 PARTICIPANTS: Has received or is receiving treatment for a solid-organ malignancy (does not hematologicapply to Group 2)
  • AddedGROUP 2 PARTICIPANTS: Diagnosis of one of the following hematologic malignancies: Chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), multiple myeloma, or survivorship care after completion of therapy for one of the above hematologic malignancies (within 5 years of completion of therapy)
  • AddedGROUP 1 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to hematologic malignancies)
  • EditedHemoglobin ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion) (≤ 180 days prior to registration)
  • EditedAlanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal (ULN) (≤ 180 days prior to registration)
  • EditedCreatinine ≤ 1.5 x ULN (≤ 180 days prior to registration)
  • AddedGROUP 2 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to solid-organ malignancies):
  • AddedHemoglobin ≥ 8.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
  • AddedPlatelet count ≥ 50,000 cells/mm\^3
  • AddedAbsolute neutrophil count ≥ 1000 cells/mm\^3
  • AddedAlanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x ULN
  • AddedCreatinine ≤ 1.5 x ULN
  • EditedNo clinical suspicion of hypothyroidism within 180 days prior to registration [(if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone ([TSH)] < 5 milli-international units per liter (mIU/L) is required])
Exclusion criteria
  • AddedExamples of antidiabetic drugs include: Insulin, sulfonylureas, sodium-glucose co-transporter subtype 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonists/dual incretin agonists, and related agents
  • AddedAny of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
  • AddedPregnant persons
  • AddedNursing persons
  • AddedPersons of childbearing potential who are unwilling to employ adequate contraception. (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
  • AddedGROUP 2 PARTICIPANTS: Patients who have been hospitalized (> 24 hours) in the previous 2 months or who will require hospitalization (for anti-cancer therapy) within the next 3 months
  • AddedGROUP 2 PARTICIPANTS: Prior allogeneic transplant
  • AddedGROUP 2 PARTICIPANTS: Chimeric antigen receptor T cell (CAR-T), or autologous transplant within the last 180 days
  • AddedGROUP 2 PARTICIPANTS: T-cell engager initiation within the last 3 months (patients on stable maintenance dosing are permitted)
  • AddedGROUP 2 PARTICIPANTS: Enrolled in another interventional clinical trial
Oct 20, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in fatigue at 8 weeksTime frame: Baseline to 8 weeks
Oct 20, 2026
Secondary outcomes
2 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedChange in fatigueFatigue - FACIT-FatigueTime frame: Baseline, 4 and 8 weeks → 4 weeks, 8 weeks
  • ChangedBefore Incidence of adverse eventsNow Patient-reported Toxicities - Ginseng Symptom Experience DiaryTime frame: Up to 8 weeks
  • Time framePercentage of patients who perceive moderate to very much better fatigueAt 8 weeks → 4 weeks, 8 weeks
  • DescriptionPercentage of patients who perceive moderate to very much better fatigue: how it is measured was reworded
Oct 20, 2026
Show all 2 updates
  1. Oct 20, 2026
    Enrollment 160→222
    Eligibility 5 inclusion criteria edited, 8 added; 10 exclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • EditedGROUP 1 PARTICIPANTS: Has received or is receiving treatment for a solid-organ malignancy (does not hematologicapply to Group 2)
    • AddedGROUP 2 PARTICIPANTS: Diagnosis of one of the following hematologic malignancies: Chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), multiple myeloma, or survivorship care after completion of therapy for one of the above hematologic malignancies (within 5 years of completion of therapy)
    • AddedGROUP 1 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to hematologic malignancies)
    • EditedHemoglobin ≥ 10.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion) (≤ 180 days prior to registration)
    • EditedAlanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x upper limit normal (ULN) (≤ 180 days prior to registration)
    • EditedCreatinine ≤ 1.5 x ULN (≤ 180 days prior to registration)
    • AddedGROUP 2 PARTICIPANTS: The following laboratory values obtained ≤ 180 days prior to registration (does not apply to solid-organ malignancies):
    • AddedHemoglobin ≥ 8.0 g/dL (patients must not have been transfused in the preceding 90 days to meet this criterion)
    • AddedPlatelet count ≥ 50,000 cells/mm\^3
    • AddedAbsolute neutrophil count ≥ 1000 cells/mm\^3
    • AddedAlanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 3 x ULN
    • AddedCreatinine ≤ 1.5 x ULN
    • EditedNo clinical suspicion of hypothyroidism within 180 days prior to registration [(if clinical suspicion of hypothyroidism exists, a documented thyroid stimulating hormone ([TSH)] < 5 milli-international units per liter (mIU/L) is required])
    Exclusion criteria
    • AddedExamples of antidiabetic drugs include: Insulin, sulfonylureas, sodium-glucose co-transporter subtype 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonists/dual incretin agonists, and related agents
    • AddedAny of the following because this study involves an investigational agent whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown:
    • AddedPregnant persons
    • AddedNursing persons
    • AddedPersons of childbearing potential who are unwilling to employ adequate contraception. (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
    • AddedGROUP 2 PARTICIPANTS: Patients who have been hospitalized (> 24 hours) in the previous 2 months or who will require hospitalization (for anti-cancer therapy) within the next 3 months
    • AddedGROUP 2 PARTICIPANTS: Prior allogeneic transplant
    • AddedGROUP 2 PARTICIPANTS: Chimeric antigen receptor T cell (CAR-T), or autologous transplant within the last 180 days
    • AddedGROUP 2 PARTICIPANTS: T-cell engager initiation within the last 3 months (patients on stable maintenance dosing are permitted)
    • AddedGROUP 2 PARTICIPANTS: Enrolled in another interventional clinical trial
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in fatigue at 8 weeksTime frame: Baseline to 8 weeks
    Secondary outcomes 2 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedChange in fatigueFatigue - FACIT-FatigueTime frame: Baseline, 4 and 8 weeks → 4 weeks, 8 weeks
    • ChangedBefore Incidence of adverse eventsNow Patient-reported Toxicities - Ginseng Symptom Experience DiaryTime frame: Up to 8 weeks
    • Time framePercentage of patients who perceive moderate to very much better fatigueAt 8 weeks → 4 weeks, 8 weeks
    • DescriptionPercentage of patients who perceive moderate to very much better fatigue: how it is measured was reworded
    + 3 other changes: conditions, data sharing statement and index terms
  2. Oct 6, 2026
    Primary completion Nov 30, 2026→Dec 30, 2027
    Study completion Nov 30, 2026→Dec 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06395441
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Aug 1, 2024
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Daniel S. Childs, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: American ginseng

Start the discussion